Stephen Furlong Sells 10,845 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 10,845 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total transaction of $41,536.35. Following the completion of the transaction, the chief financial officer now directly owns 471,727 shares in the company, valued at $1,806,714.41. This trade represents a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stephen Furlong also recently made the following trade(s):

• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Stock Up 11.8 %

Shares of NASDAQ:STIM opened at $4.36 on Friday. Neuronetics, Inc. has a 52-week low of $0.52 and a 52-week high of $5.07. The stock has a market cap of $132.33 million, a P/E ratio of -3.54 and a beta of 2.17. The business has a fifty day moving average of $2.20 and a two-hundred day moving average of $1.41. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90.

Institutional Investors Weigh In On Neuronetics

A number of hedge funds have recently modified their holdings of STIM. HighTower Advisors LLC raised its stake in Neuronetics by 55.5% during the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Neuronetics during the 3rd quarter worth approximately $53,000. JPMorgan Chase & Co. raised its position in shares of Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after buying an additional 54,442 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Neuronetics by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares during the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.